Clinical Trials · NCT02032784

Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

TerminatedPhase 4Octreotide (Prohibited)
Phase
Phase 4
Recruitment status
Terminated
Sponsor
AdventHealth
Enrollment
33
Start date
Mar 2014
Locations
1 site, United States
Primary endpoint
Post endoscopic mucosal resection bleeding
View Octreotide compound reference